Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13811600 | 1.00 | CYP19A1 (0.40) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL995834 | 1.00 | CYP19A1 (0.40) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL17886845 | 0.91 | CYP19A1 (0.41) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL28296372 | 0.83 | CYP19A1 (0.37) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL13073268 | 0.82 | CYP19A1 (0.46) | CYP19A1CHRM3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1682649 | 0.82 | CYP19A1 (0.50) | CYP19A1CHRM3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3676448 | 0.81 | CYP19A1 (0.36) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL3678287 | 0.81 | CYP19A1 (0.36) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL9050652 | 0.81 | MAPT (0.50) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 | |
| SCHEMBL985386 | 0.81 | CYP19A1 (0.39) | CYP19A1CHRM3SMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-20 | — | — | US | claimed |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-09-03 | — | — | US | claimed |
| US-11161102-B2 | Iminium salt organocatalysts, method of making, and methods of using | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190344253-A1 | IMINIUM SALT ORGANOCATALYSTS, METHOD OF MAKING, AND METHODS OF USING | UNIV VIRGINIA PATENT FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2017223287-A1 | IMINIUM SALT ORGANOCATALYSTS, METHODS OF MAKING, AND METHODS OF USING | UNIVERSITY OF VIRGINIA (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-05-15 | — | — | US | disclosed |
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829342-B2 | composition including a complex of a metal, a tetradentate ligand, at least one ancillary ligand, and a counterion is used for selective sp3 C H bond oxidation; includes a N-heterocyclic-N,N'-bis(pyridyl)-ethane-1,2-diamine group or a N,N'-bis(heterocyclic)-N,N'-bis(pyridyl)-ethane-1,2-diamine group | THE BOARD OF TRUSTEES OF THE UNIVERSIY OF ILLINOIS (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | AOC3, SOD3, AP3S1 | CYP19A1 4561/4885CHRM3 1009/4885SMN1; SMN2 3486/4885 |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | AOC3, SOD3, AP3S1 | CYP19A1 4561/4885CHRM3 1009/4885SMN1; SMN2 3486/4885 |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | CYP19A1 987/4885CHRM3 783/4885SMN1; SMN2 4749/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | CYP19A1 921/4885CHRM3 747/4885SMN1; SMN2 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.